Investigational drug · Phase 2
JK07
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "JK07"
First trial start
2024
Mar 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JK07", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "JK07" as an intervention, largest first.
- Study of JK07 in Patients With Chronic Heart FailurePivotal-lookingActive, not recruiting
Salubris Biotherapeutics IncIndustry
NCT06369298 · 282 participants (planned) · Start Mar 28, 2024 · Primary completion Oct 31, 2026
Drug: JK07; Placebo · For: Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 62 sites in all
Salubris Biotherapeutics IncIndustry
NCT04210375 · 14 participants · Start Sep 21, 2020 · Primary completion Jun 8, 2023
Drug: JK07; Matching Placebo · For: Heart Failure With Reduced Ejection Fraction
Sites: Tucson, Arizona; Stanford, California; Boston, Massachusetts · 7 sites in all
Salubris Biotherapeutics IncIndustry
NCT05322616 · 0 participants · Start Oct 21, 2022 · Primary completion May 26, 2023
Drug: JK07; Matching Placebo · For: Heart Failure With Preserved Ejection Fraction
Sites: Stanford, California; Boston, Massachusetts; Rochester, Minnesota · 7 sites in all
Salubris Biotherapeutics IncIndustry
NCT07221513 · 0 participants · Start Dec 15, 2025 · Primary completion Apr 16, 2026
Drug: JK07 · For: HFrEF - Heart Failure With Reduced Ejection Fraction; HFpEF - Heart Failure With Preserved Ejection Fraction; Group 2 Pulmonary Hypertension
Sites: Tulsa, Oklahoma
Newest research
PubMed records naming it or its code names, newest first.
- ERBB4 activation as a new therapy for atrial remodeling and fibrillation.
Van Fraeyenhove J, Tubeeckx MRL, Goovaerts B, et al. · Heart Rhythm 2026
- ERBB4 activation prevents microvascular dysfunction in a large animal model of hypertensive heart disease.
Tubeeckx MRL, Bringmans T, Goovaerts B, et al. · Am J Physiol Heart Circ Physiol 2026
- Preferential HER4 stimulation preserves neuregulin-induced improvement of myocardial function.
Murphy SL, Tang WHW, Zhuang X, et al. · NPJ Drug Discov 2026
- Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction.
Tang WHW, Steiner J, Kassi M, et al. · JACC Basic Transl Sci 2025
- Effects of potassium-solubulizing and photosynthetic bacteria on tolerance to salt stress in maize.
Feng K, Cai Z, Ding T, et al. · J Appl Microbiol 2019
Also in development for Heart Failure With Reduced Ejection Fraction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.